Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STORM: Selinexor in Refractory Multiple Myeloma
NCT02336815Phase 2Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- May 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of selinexor in multiple myeloma (MM), sponsored by Karyopharm Therapeutics Inc.. Started May 2015; status: completed.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02336815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02336815.